Oxidative stress is being recognized as a key factor in the progression of chronic liver disease (CLD), especially non-alcoholic fatty liver disease (NAFLD). Many NAFLD treatment guidelines recommend the use of antioxidants, especially vitamin E. Many prospective studies have described the beneficial effects of such agents for the clinical course of NAFLD. However, as these studies are usually short-term evaluations, lasting only a few years, whether or not antioxidants continue to exert favorable long-term effects, including in cases of concomitant hepatocellular carcinoma, remains unclear. Antioxidants are generally believed to be beneficial for human health and are often commercially available as health-food products. Patients with lifestyle-related diseases often use such products to try to be healthier without practicing lifestyle intervention. However, under some experimental NAFLD conditions, antioxidants have been shown to encourage the progression of hepatocellular carcinoma, as oxidative stress is toxic for cancer cells, just as for normal cells. In this review, we will highlight the paradoxical effects of antioxidants against NAFLD and related hepatocellular carcinoma.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease associated with obesity and metabolic syndrome [1, 2] . The deposition of lipids in the liver induces inflammation, insulin resistance, and hepatic steatosis [3] . Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD that causes cirrhosis and hepatocellular carcinoma (HCC) because of persistent inflammation associated with hepatic steatosis [4, 5] . The mechanism underlying the development of NASH from simple steatosis, namely non-alcoholic fatty liver (NAFL), has been considered as either a two-hit theory or a multiple hit-process [6] [7] [8] . The two-hit theory comprises a first hit of hepatic steatosis and second hit of several cellular stress responses, such as oxidative stress or endoplasmic reticulum (ER) stress. Given that the second hits are multifactorial and hepatic steatosis may be induced via hepatic inflammation, the process has recently been expressed as a multiple parallel hit process or multiple hit process [8] .
Oxidative stress is a cellular stress associated with NASH progression. Reactive oxygen species (ROS) are generated during free fatty acid metabolism in microsomes, peroxisomes, and mitochondria, and comprise an established source of oxidative stress [9] . Oxidative stress is increased through the generation of ROS, as well as by defects in redox defense mechanisms involving glutathione (GSH), catalase or superoxide dismutase (SOD), and it induces various events related to not only
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Hepatocellular carcinoma (HCC) is the major malignant liver tumor and the main cause of death in NAFLD/NASH patients. Oxidative stress is strongly associated with hepatocarcinogenesis and cancer progression. However, the effects on cancer-free patients and patients with HCC are likely different. Oxidative stress has a driving effect on carcinogenesis while also exerting toxicity against cancer cells. This contradiction will be discussed in this section.
Oxidative Stress in NASH-Hepatocarcinogenesis
Oxidative stress is reported to induce various events related to carcinogenesis such as DNA damage, tissue remodeling, and alterations in gene expression [11, 49, 50] . ROS production is stimulated by inflammatory factors, and oxidative stress promotes oncogenic transformation due to DNA-damage. ROS activates various pathways, such as Wingless-type MMTV intefration site family (Wnt) /β-catenin, NF-kB, or myc proto-oncogene protein (c-Myc)/Transforming growth factor (TGF)-α. This activation also occurs in carcinogenesis in liver cancer. Inducible nitric oxide synthase (iNOS), which produces nitrogen monoxides (NO), correlates with chronic inflammation, cell proliferation, DNA repair, migration, and angiogenesis [51] . The iNOS activity is important for endothelial stress gene expression, which protects against oxidative stress, and may be the key modulator of hepatocarcinogenesis.
8-hydroxydeoxyguanosine (8-OHdG), which is produced by DNA-damage with ROS, reflects the amount of oxidative stress and generates a point mutation in DNA double strands. Kawanishi et al. reported that 8-OHdG, which is a reliable marker for oxidative stress in the liver, strongly correlates with infection-related carcinogenesis via chronic inflammation [52] . Seki et al. reported that the 8-OHdG expression in the liver tissue is related to the pathological features of NAFLD and hepatocarcinogenesis [53] .
Adenosine monophosphate activated protein kinase (AMPK) is a highly conserved heterodimeric serine-threonine kinase that plays a role in cellular energy homeostasis and different fundamental cellular processes such as the cellular proliferation, survival, and metabolism. It serves as an energy sensor in eukaryotic cells and bridges metabolism to carcinogenesis [54] . Its activated form (phospho (p)-AMPK) is down-regulated in HCC tissues from patients and low levels of p-AMPK correlate with a poor prognosis, indicating the importance of AMPK signaling in HCC [55] . AMPK signaling has recently been indicated to correlate with inflammatory responses, as the energy metabolism in immune cells is related to immunoregulation [56] . Under many oxidative stress-related conditions, such as diabetes or dyslipidemia, a diminished AMPK activity has been shown to be associated with tissue oxidative stress [57, 58] .
As mentioned above, oxidative stress is linked to the progression from NAFLD to HCC. The correlation of AMPK and clinical conditions encourage us to control AMPK as a cancer regulator.
Antioxidant Treatment Effects on Prevention of NASH-Hepatocarcinogenesis
Given that advanced chronic liver disease is the strongest risk factor for hepatocarcinogenesis, antioxidant treatments can be an important approach to preventing HCC development from NASH. The effect of these agents concerning whether they have the properties to protect against hepatocarcinogenesis should include an improvement in liver fibrosis improvement.
Vitamin E was reported to prevent hepatocarcinogenesis via the down-regulation of iNOS and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [59] . Many clinical studies have reported that vitamin E improves NAFLD and prevents the development of HCC [13, [60] [61] [62] . However, these studies were all performed over a relatively short period (i.e., within two years). Hepatocarcinogenesis progresses from NAFL/NASH to cirrhosis over a long period of time, and middle-aged men carry risks of hepatocarcinogenesis even at an early stage of NAFLD [63] . The long-term outcomes must be evaluated in order to judge the true efficacy of antioxidant therapy for NASH-hepatocarcinogenesis.
Many candidate antioxidant agents may show favorable effects on NASH and NASHrelated hepatocarcinogenesis.
Anti-diabetic agents such as metformin, pioglitazone, glucagon-like peptide 1-receptor agonists (GLP-1 RAs), and dipeptidyl-peptidase-4 inhibitors (DPP-4Is) were recently found to show favorable effects on the NAFLD clinical course [7, 64, 65] . Metformin and pioglitazone in particular are regarded as anti-oxidant agents. Metformin is the most well-studied AMPK-activating agent. Metformin-related AMPK pathway activation is involved in many cell types including T cells, B cells, hepatocytes, and even liver fibrosis-inducing hepatic stellate cells (HSCs). In in vitro and in vivo models (mice), metformin suppressed alpha smooth muscle actin (α-SMA) expression via AMPK activation and the inhibition of the succinate-related pathway in (HSCs) [66] . HSC activation is an important step in hepatocarcinogenesis. In addition, metformin induces the production of the antioxidant enzyme, heme oxygenase-1 (HO-1) in human endothelial cells via the nuclear factor erythroid 2-related factor (Nrf2) signaling pathway [67] . Determining metformin's long-term effects on reducing the risk of hepatocarcinogenesis might require further long-term studies.
Pioglitazone is a thiazolidinedione activating peroxisome proliferator-activated receptor (PPAR) γ that improves the insulin resistance and is used to treat type 2 diabetes. A six-month randomized study of pioglitazone revealed a reduction in necroinflammation of liver histopathology with no reduction in fibrosis [68] . L-carnitine is an essential nutrient and an important molecule in regulating mitochondrial and peroxisomal metabolism [69] . A recent randomized controlled study indicated histological improvement of liver fibrosis after 18 months with pioglitazone for NASH in patients with concomitant type 2 diabetes [70] . This agent may therefore be effective for inhibiting NAFL progression to NASH and hepatocarcinogenesis.
Flavonoids are heterogeneous polyphenols found in various plants, such as fruits, vegetables, and green tea that reportedly exert antioxidative function protecting the liver tissue from damage caused by ROS [71] . A mixture of flavonolignans and minor polyphenolic compounds, derived from the milk thistle plant (Silybum marianum) known as silymarin, is said to be an antioxidative agent [72] . Salomone et al. reported that silibinin, the main component of silymarin, restored nicotinamide adenine dinucleotide (NAD+) levels, and played a protective role against NAFLD [73] . In a randomized, double-blind, placebo-controlled study, silymarin at 700 mg three times daily for 48 weeks significantly ameliorated liver fibrosis in NASH patients [74] . Silymarin may therefore be a promising agent for the treatment of NAFLD/NASH patients.
L-carnitine acts as an antioxidant mediator by controlling the β-oxidation cycle and adenosine triphosphate (ATP) generation [75] . L-carnitine is well known as a fat-burning supplement; however, it has recently attracted attention as an anti-cancer agent because of its effects as an antioxidant, apoptosis inducer, and inhibitor of histone deacetylase [76] [77] [78] [79] . We previously reported that L-carnitine controls the mitochondrial function in hepatic non-cancerous tissue from a mouse NASH model by upregulating the Lactobacillales population related to the secondary bile acid production in the gut microbiota [76] . L-carnitine does not eliminate oxidative stress but rather controls the oxidative balance to aid the mitochondrial function. This might be a better approach to regulating oxidative stress.
High levels of plasma free fatty acids increase the levels of hepatic free fatty acids. Long-chain fatty acids taken up by mitochondria as complexes with L-carnitine are subsequently metabolized in β-oxidation pathways. Under oxidative stress, oxidative reactions convert oxidized cofactors (NAD+ and flavin adenine dinucleotide (FAD)) into reduced cofactors (nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide H2 (FADH2)) and deliver electrons to the respiratory chain. An imbalance between the increased delivery of electrons to the respiratory chain and the decreased outflow from the respiratory chain causes electrons and ROS products to accumulate. Antioxidant defenses, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), or catalase, can metabolize O 2 · and H 2 O 2 to non-toxic H 2 O. However, the Fenton and/or Haber-Weiss reactions generate highly reactive, toxic, hydroxyl radicals (OH). Vitamin E as a general cytotoxic ROS scavenger erases oxidative stress. Metformin activates AMPK and induces antioxidant gene transcription, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) activates Nrf2 via a mechanism possibly similar to that of metformin. L-carnitine supports the mitochondrial function to increase the long-chain fatty acid uptake. In NASH patients, oxidative stress works as toxic from NASH progression to cancer development. However, in cancer patients, oxidative stress should be maintained to some degree in order to control cancer via toxic oxidative stress reactions. To control cancer progression, AMPK/mammalian target of rapamycin (mTOR) signaling has an important function that would be a target to intervene.
Antioxidant Treatment Effects on Liver Cancer
Various treatments have been proposed for HCC, such as surgical approaches (e.g., liver resection, liver transplantation), radio frequency ablation, transcatheter arterial chemoembolization, and chemotherapy [80] . However, HCC remains incurable because of the low response rate and frequent recurrence based on chronic liver inflammation and fibrosis. Many reports have described the usage of antioxidant therapies for HCC, but their efficacy still remains unclear [81] [82] [83] .
Metformin inhibits the cell growth of HCC by regulating AMPK activation and inducing apoptosis [84] . The effect of metformin on NASH-related HCC in mouse models has been reported, but the clinical effect in humans is unclear [85] .
The AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) activates Nrf2 protein, which binds to Kelch-like ECH associated protein 1 (Keap1), a protein that exists in the cytoplasm in an inactive form [86] . AICAR may be a candidate for treating liver cancer.
Flavonoid and polyphenols have been shown to exert antitumor effects through the control of various molecular pathways [81, 87] . Curcumin is an antioxidant polyphenol compound reported to exert antitumor activities by inhibiting the vascular endothelial growth factor (VEGF) expression and phosphoinositide 3-kinase (PI3K)/v-Akt murine thymoma viral oncogene (Akt) signaling [82] . The newly confirmed antioxidant silymarin has also been analyzed for its utility in preventing hepaticarcinogenesis [73] .
L-carnitine is a mitochondria supporting agent that may be useful for controlling oxidative stress in HCC patients. Our previous report showed that the tumor number and maximum tumor size were decreased in NASH-HCC mouse models than control diet [76] . In that experiment, L-carnitine was administered from the early onset of NASH, and the liver tumor outcomes were assessed afterwards. Under such conditions, L-carnitine improved the NASH pathogenesis resulting in decreased NASH related hepatocarcinogenesis and so is difficult to conclude whether its use is beneficial for HCC. To answer this point, we next examined the effect of L-carnitine administration after hepatocarcinogenesis in NASH-related cholangiocarcinoma-like tumors [88] . L-carnitine resulted in a good outcome for this model, suggesting it might be an effective antioxidant even after cancer development.
As above, many candidate antioxidant treatments have been proposed for HCC; however, the clinical investigations on this point are inadequate at present. To administer antioxidants for cancer stages, we must consider the oxidative stress-related environment adequately (Figure 1) .
Recently, oral chemotherapeutic multi-kinase inhibitors such as sorafenib have been widely used to control advanced-stage HCC. Sorafenib inhibits tumor cell proliferation and angiogenesis through the inactivation of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and the serine-threonine kinase Raf-1, which participates in the Rat sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) signal cascade [89] . Recently, other multi-kinase inhibitors such as lenvatinib, regorafenib, cabozantinib, and ramucirumab have also been developed [90] [91] [92] . Recent clinical experience with sorafenib has indicated that acquired drug resistance can occur over a long period of drug administration. Thus, in these stages of HCC, the effects of accompanying agents such as antioxidants on the drug resistance should be investigated. Accumulating data indicate that autophagy and phosphoinositide 3-kinase (PI3K)/Akt signaling are associated with acquired resistance to sorafenib in HCC. The AMPK/mTOR signaling pathway had been demonstrated to be important in autophagy. A high sustained glucose condition produces advanced glycation products (AGEs) which damage many organs including the liver. The receptor for AGE (RAGE) has been shown to be overexpressed in HCC promoting proliferation. In addition, RAGE induced sorafenib resistance in in vitro and in vivo xenograft models [93] . A reduction in RAGE was also found to be able to increase autophagy and eliminate sorafenib resistance in vitro via the AMPK pathway activation. Metformin was able to reduce RAGE expression and helped rescue cells from sorafenib resistance. Metformin might therefore be useful for eliminating sorafenib resistance in HCC; however, one clinical study reported a bad outcome for patients administered metformin with sorafenib [94] .
beneficial for HCC. To answer this point, we next examined the effect of L-carnitine administration after hepatocarcinogenesis in NASH-related cholangiocarcinoma-like tumors [88] . L-carnitine resulted in a good outcome for this model, suggesting it might be an effective antioxidant even after cancer development.
As above, many candidate antioxidant treatments have been proposed for HCC; however, the clinical investigations on this point are inadequate at present. To administer antioxidants for cancer stages, we must consider the oxidative stress-related environment adequately (Figure 1 ). Administering sorafenib efficacy-supporting agents is an approach to resolving drug resistance as mentioned above with metformin. The oxidative stress-inducing agent tetrandrine, a bisbenzylisoquinoline alkaloid, has been shown to exert synergistic anti-tumor activity with sorafenib by increasing ROS [95] . More data on such combination therapy with sorafenib will be required to draw more solid conclusions.
Immune checkpoint molecules including programmed cell death-1 (PD-1) and programmed cell death-1 ligand (PD-L1), are promising new therapeutic agents for the treatment of various cancers including HCC [96] . Nivolumab, an anti-PD-1 antibody, was approved by the Food and Drug Administration (FDA) and is a key drug for the treatment of HCC dramatically improving the survival of many cancers, including solid-tumors; however, 30 to 50% of patients are unresponsive [97] . To overcome this unresponsiveness, several combination treatments have been attempted. An in vivo analysis of CD8+ T cells treated with PD-1 antibody revealed that a highly proliferative fraction could be found in the draining lymph node indicating that tumor priming was necessary for CD8+ T cell activation [98] . These highly proliferative CD8+ T cells contained more cellular ROS, a larger mitochondrial mass, higher mitochondrial potential, and more mitochondrial superoxide than CD8+ T cells without PD-1 antibody treatment, indicating the activation of mitochondria in T cells. Several mitochondrial function activators have been tested for their additive effects of PD-1 blockade with successful results. Of them, the PPAR-α agonist bezafibrate showed a particularly promising response. Given that bezafibrate is a standard agent for treating high triglyceride levels, this combination might be useful for combination therapy. The relationship between oxidative stress, antioxidants, and PD-1/PD-L1 needs further study and clinical trials to resolve the issue of a lack of responsiveness to anti-PD-1 antibody therapy.
Cautions of Antioxidants on Liver Cancer Initiation and Maintenance
Whether or not antioxidant agents prevent cancer risks remains controversial. The U.S. Preventive Services Task Force (USPSTF) stated that the current evidence is insufficient to assess the balance of benefits and harms of vitamins [99] . In particular, excessive doses of vitamins may induce negative effects. Four randomized controlled trials (RCTs) of vitamin E included in the USPSTF comments showed no significant effect on the incidence of all types of cancer or cancer mortality rates. However, one RCT assessing the risk of prostate cancer with vitamin E administration found a 17% increase in the prostate cancer incidence with this supplement [100] . Since a large prospective study to confirm the HCC risks for NASH is difficult to perform and requires a long observation time (although there are some ongoing studies), we should attempt to determine the optimum treatment approach based on short-term data from small populations and experimental data.
Oxidative stress is a crucial event for cancer initiation; however, it also has important roles in cancer prevention. Stem cell-like cancer cells have powerful antioxidative properties that protect them from oxidative stress and thus prevent self-apoptosis [101] . The expression of CD44 variant 9 (CD44v9) has recently been investigated as a functional marker of stem-like cells in many types of cancers [102] . The interaction of CD44v9 with xc-Substrate-specific Subunit (xCT), also called the glutamate/cysteine antiporter solute carrier family 7 member 11 (SLC7A11), a subunit of the glutamate-cystine transporter system xc-, stabilizes the latter and thereby potentiates cancer cells to promote glutathione synthesis and reduce the activity of cellular redox system, resulting in resistance to toxic oxidative stresses [103] . Inducing oxidative stress in cancer patients is an approach that is being investigated as a cancer treatment in several clinical trials [104] . However, this approach is likely to also be toxic to normal cells and may lead to the induction of further carcinogenesis. Furthermore, given that treatment-resistant cancer stem cells can still escape toxic oxidative stress, maintaining moderate oxidative stress is a critical point of anti-oxidative stress treatment for cancer patients.
Mitochondrial function-supporting agents, such as metformin or L-carnitine, might be good therapies to investigate in large-scale prospective studies in humans. In cancer patients, the drug effects should be analyzed according to the stages of the cancer. When tumors have been completely resected or ablated, a standard anti-oxidant approach may be effective for preventing new hepatocarcinogenesis. When tumors have not been ablated completely but can be managed with local treatment, such as transcatheter arterial chemo-embolization (TACE), mitochondrial function-supporting agents, such as metformin or L-carnitine, might be useful approaches for controlling the oxidative-antioxidative stress balance. When tumors are not being treated with local therapies but instead managed with anti-cancer agents, presently multi-kinase inhibitors such as sorafenib, regorafenib and lenvatinib, oxidative stress may be an important cellular stress to cancer cells not to be eliminated. As mentioned in previous section, oxidative stress-inducing agents may compound the effects of sorafenib [95] . However, even the favorably reported antioxidant metformin might adversely affect the clinical outcome in patients with HCC receiving the multi-kinase inhibitor sorafenib [94] .
L-carnitine is a candidate drug that has shown good efficacy even after cancer has already developed. We previously investigated the effects of the standard anti-oxidant agents vitamin E and L-carnitine and found that only L-carnitine reduced the number of liver tumors [88] . Vitamin E administration induced HO-1 protein expression in cancer tissue, resulting in an increase in the number of stem-like cancer cells. Furthermore, L-carnitine administration improved the Lactobacillales population and the balance of bile acid (primary to secondary bile acid), while vitamin E did not affect the intestinal environment. These findings show that vitamin E strongly ameliorates the oxidative stress in both cancer cells and normal cells, while L-carnitine works as an "oxidative stress balancer". An "oxidative stress eraser" such as vitamin E might therefore be unsuitable for the treatment of cancer patients. However, even L-carnitine carries the possibility of an increased risk of experimental HCC [105] . A mouse HCC model of diethylnitrosamine (DEN)-injected mice fed a high-fat diet showed the predominance of acylcarnitine species in the tumors according to a metabolomic profiling analysis. Intracellular long-chain fatty acids are esterified to acyl-coenzyme A and conjugated with carnitine resulting in acylcarnitine by carnitine palmitoyltransferase 1 (CPT 1). The acylcarnitine is then converted back to acyl-coenzyme A by CPT2 and enters the β-oxidation pathway. Of note, the CPT2 expression was diminished in the HCC tumors inducing acylcarnitine deposition. In this mouse model, L-carnitine supplementation resulted in an increased amount of acylcarnitines and enhanced HCC tumorigenesis. These conflicting results suggest that the HCC-preventive effects of L-carnitine might require a preserved CPT2 function in order to avoid inducing the accumulation of acylcarnitines.
It should be noted that almost all antioxidants can elicit unfavorable effects on carcinogenesis under certain conditions. We must bear these facts in mind and thus perform antioxidant supplementation judiciously. We can use antioxidant for NASH, while should decide whether to stop after HCC development (Figure 2 ).
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Conclusions
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NAFLD is a major lifestyle-related disease, and nutritional support is an important approach to its treatment. Antioxidant therapy, such as vitamin E administration, is effective for preventing NASH progression; however, the long-term outcomes of this therapy are unclear, especially in precancerous and cancer patients. Antioxidant therapy should be prescribed according to the clinical condition of the patients, such as those with NAFL, NASH, advanced NASH, cancer with successful ablation, cancer with relative ablation, and advanced cancer requiring anti-cancer agents. In HCC patients, antioxidant treatment should be carefully managed, as these agents can also act against tumor resolution.
